论文部分内容阅读
目的探讨c-Met在甲状腺乳头状癌患者肿瘤组织中的表达及其临床意义。方法选取2010年6月-2016年6月住院治疗的甲状腺乳头状癌、甲状腺肿、甲状腺腺瘤女性患者各50例,分析全部患者临床、病理及随访资料,将甲状腺乳头状癌患者作为观察组,甲状腺腺瘤及结节性甲状腺肿患者作为对照A组与对照B组,分别观察并记录c-Met在甲状腺乳头状癌患者肿瘤组织中的表达情况,c-Met在结节性甲状腺肿、甲状腺腺瘤患者病理组织中的表达情况。结果在对各组进行年龄、基因突变、基因扩增、自分泌/旁分泌信号和c-Met活化、蛋白的超表达分析发现,观察组在基因突变、自分泌/旁分泌信号和c-Met活化、蛋白的超表达中表达水平明显高于对照组,(P<0.05);在基因扩增方面,观察组与对照组有明显差异,在基因扩增方面观察组表达水平偏低(P<0.05)。结论 c-Met在甲状腺乳头状癌患者肿瘤组织中的表达出现变异,cMet在甲状腺乳头状癌的治疗方面具有临床意义。
Objective To investigate the expression of c-Met in the tumor tissue of patients with papillary thyroid carcinoma and its clinical significance. Methods Fifty patients with thyroid papillary thyroid carcinoma, goiter and thyroid adenoma were selected from June 2010 to June 2016 in our hospital. The clinical, pathological and follow-up data of all patients were analyzed. The patients with thyroid papillary carcinoma were selected as observation group , Thyroid adenoma and nodular goiter as control group A and control group B were observed and recorded c-Met in papillary thyroid carcinoma patients with tumor tissue expression, c-Met in nodular goiter, Thyroid adenoma in patients with pathological tissue expression. Results Analysis of the overexpression of proteins by age, gene mutation, gene amplification, autocrine / paracrine signaling and c-Met activation in each group found that in the observation group, mutations in the gene, autocrine / paracrine signaling and c-Met (P <0.05). There was a significant difference between the observation group and the control group in gene amplification, and the expression level in the observation group was lower than that in the control group (P < 0.05). Conclusion The expression of c-Met in tumor tissue of patients with papillary thyroid carcinoma is variable, and cMet has clinical significance in the treatment of papillary thyroid carcinoma.